Όλο το DSpace

Πλοήγηση ανά Θέμα "beta-Thalassemia"

Αποτελέσματα 1-5 από 5

    • Apolipoprotein E Polymorphism and Left Ventricular Failure in Beta-Thalassemia: A Multivariate Meta-Analysis 

      Dimou N.L., Pantavou K.G., Bagos P.G. (2017)
      Apolipoprotein E (ApoE) is potentially a genetic risk factor for the development of left ventricular failure (LVF), the main cause of death in beta-thalassemia homozygotes. In the present study, we synthesize the results ...

    • Fibroblast Growth Factor 23 (FGF23) and Klotho Protein in Beta-Thalassemia 

      Stefanopoulos D., Nasiri-Ansari N., Dontas I., Vryonidou A., Galanos A., Psaridi L., Fatouros I.G., Mastorakos G., Papavassiliou A.G., Kassi E., Tournis S. (2020)
      Derangements in phosphate and calcium homeostasis are common in patients with beta-thalassemia. Fibroblast growth factor 23 (FGF23) is among the main hormones regulating phosphate levels, while several studies underline ...

    • In vivo base editing by a single i.v. vector injection for treatment of hemoglobinopathies 

      Li C., Georgakopoulou A., Newby G.A., Everette K.A., Nizamis E., Paschoudi K., Vlachaki E., Gil S., Anderson A.K., Koob T., Huang L., Wang H., Kiem H.-P., Liu D.R., Yannaki E., Lieber A. (2022)
      Individuals with β-thalassemia or sickle cell disease and hereditary persistence of fetal hemoglobin (HPFH) possessing 30% fetal hemoglobin (HbF) appear to be symptom free. Here, we used a nonintegrating HDAd5/35++ vector ...

    • Restless legs syndrome/Willis–Ekbom disease prevalence in beta thalassemia patients 

      Dimitriadou E., Giannaki C.D., Tsekoura M., Stefanidis I., Hadjigeorgiou G.M., Lavdas E., Karatzaferi C., Sakkas G.K. (2018)
      Purpose: Both beta thalassemia and restless legs syndrome (RLS) patients share some common pathophysiological characteristics related to iron handling. In the present study, the aim was to explore the prevalence of RLS as ...

    • Treatment of chronic hepatitis C with direct-acting antivirals in patients with β-thalassaemia major and advanced liver disease 

      Sinakos E., Kountouras D., Koskinas J., Zachou K., Karatapanis S., Triantos C., Vassiliadis T., Goulis I., Kourakli A., Vlachaki E., Toli B., Tampaki M., Arvaniti P., Tsiaoussis G., Bellou A., Kattamis A., Maragkos K., Petropoulou F., Dalekos G.N., Akriviadis E., Papatheodoridis G.V. (2017)
      Interferon-based regimens for chronic hepatitis C (CHC) were often deferred in patients with β-thalasaemia major (β-TM) due to poor efficacy and tolerance. Current guidelines recommend direct-acting antivirals (DAAs) for ...